Health Alert!
Subscribe to our Daily Roundup Email
Washington – Two Food and Drug Administration advisory panels will meet Monday to discuss the heart attack risk of Avandia, a popular diabetes drug.
The Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees also are expected to talk about Actos, the other medication in the same class as Avandia.
The FDA set up the meeting after The New England Journal of Medicine posted a paper May 21 that suggested Avandia could increase the risk of heart attack, and was Reported at Vos Iz Neias. [usatoday]